slightly earlier (week 6), again with an early trend apparent by week 4. Global improvement, favoring fluoxetine, was significant by week 4. As in the open-label trials, these investigators found that there was no statistical interaction between response to fluoxetine against aggression or irritability and presence of current mood or anxiety disorder. Simi-larly, there was no effect of fluoxetine on alcohol use during the trial and no interaction between changes in alcohol use and improvements in aggression and irritability with fluoxetine. Given the prevalence of depression in BPD, the paucity of controlled studies of antidepressants, especially older tricyclic and heterocyclic antidepressants is striking. An important, although puzzling, finding is the apparent independence of antidepressant effects from a comorbid diagnosis of major depression or affective BPD subtype, a past

DOI link for slightly earlier (week 6), again with an early trend apparent by week 4. Global improvement, favoring fluoxetine, was significant by week 4. As in the open-label trials, these investigators found that there was no statistical interaction between response to fluoxetine against aggression or irritability and presence of current mood or anxiety disorder. Simi-larly, there was no effect of fluoxetine on alcohol use during the trial and no interaction between changes in alcohol use and improvements in aggression and irritability with fluoxetine. Given the prevalence of depression in BPD, the paucity of controlled studies of antidepressants, especially older tricyclic and heterocyclic antidepressants is striking. An important, although puzzling, finding is the apparent independence of antidepressant effects from a comorbid diagnosis of major depression or affective BPD subtype, a past

slightly earlier (week 6), again with an early trend apparent by week 4. Global improvement, favoring fluoxetine, was significant by week 4. As in the open-label trials, these investigators found that there was no statistical interaction between response to fluoxetine against aggression or irritability and presence of current mood or anxiety disorder. Simi-larly, there was no effect of fluoxetine on alcohol use during the trial and no interaction between changes in alcohol use and improvements in aggression and irritability with fluoxetine. Given the prevalence of depression in BPD, the paucity of controlled studies of antidepressants, especially older tricyclic and heterocyclic antidepressants is striking. An important, although puzzling, finding is the apparent independence of antidepressant effects from a comorbid diagnosis of major depression or affective BPD subtype, a past